Paper Details

  1. Home
  2. Paper Details

A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer.

Author: CecchiniMichael, CuiCan, FischbachNeal A, GomezChristina M, HafezNavid, HochsterHoward S, KortmanskyJeremy S, LacyJill, SabbathKert D, SpornJonathan Reed, SteinStacey, ThumarJaykumar Ranchobdhai, UbohaNataliya V, WeiWei

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This open-label phase 1b study evaluated the safety and efficacy of TAS-102 in combination with oxaliplatin (TAS-OX) in 41 patients with metastatic colorectal cancer previously treated with 5-fluorouracil, irinotecan, and oxaliplatin. The combination was safe with no unexpected toxicities. Although the objective response rate was not clinically meaningful, the study suggests potential benefit in terms of progression-free survival and overall survival in this heavily pretreated population.
Paper Details　
Original Abstract of the Article :
BACKGROUND: TAS-102, a novel antimetabolite, is approved for treatment of refractory metastatic colorectal cancer (CRC). This study sought to determine whether the addition of TAS-102 to oxaliplatin (TAS-OX) was safe and effective in metastatic CRC previously treated with oxaliplatin. METHODS: This...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/33351187

データ提供：米国国立医学図書館（NLM）

Evaluating TAS-102 and Oxaliplatin for Refractory Metastatic Colorectal Cancer

Metastatic colorectal cancer, a complex and challenging disease, has long been a formidable foe in the world of oncology. This study delves into the potential of a new combination therapy, TAS-102 and oxaliplatin, for patients whose cancer has progressed despite previous treatments. This study employed a phase 1b expansion design, meticulously escalating the dosage to determine the safe and effective limits of the combination. It's like carefully navigating a treacherous desert, ensuring the journey is safe and leads to the desired destination.

A Promising New Combination Therapy

The study revealed that TAS-102 and oxaliplatin were well-tolerated, a crucial finding in cancer treatment where side effects can be a significant burden for patients. While the combination did not result in a dramatic reduction in tumor size, it showed encouraging signs of slowing down tumor growth and extending the time before the cancer progressed. In this study, 12 out of 41 patients saw a decrease in their tumor size, which is a positive sign for those battling this disease.

Navigating the Treatment Landscape

This study offers a glimmer of hope for patients who have exhausted conventional treatment options for metastatic colorectal cancer. The combination of TAS-102 and oxaliplatin could be a valuable addition to the treatment landscape. However, it's crucial to understand that this is just one piece of the puzzle in the complex world of cancer research. More research is needed to fully understand the long-term benefits and risks of this combination.

Dr.Camel's Conclusion

This research reminds us that the journey towards finding effective cancer treatments is a long one, often resembling a sandstorm with shifting sands and unpredictable outcomes. While this combination therapy shows promise, it is crucial to stay informed about the latest research and to collaborate with healthcare professionals for personalized treatment plans.

Date :
  1. Date Completed 2021-11-12
  2. Date Revised 2022-05-03
Further Info :

Pubmed ID

33351187

DOI: Digital Object Identifier

NIHMS1652501

Related Literature

Article Analysis
・Side Effects of trifluridine and tipiracil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.